Juridical Foundation the Chemo-sero-therapeutic Research Institute

Toshihiro Maeda

Hiroshi Mizokami

Toshio Murakami

Hirofumi Higuchi

Yasuyuki Eda

Kiyoto Nishiyama

Yoshinobu Miyatsu

Keiichi Makizumi

Satoshi Koyanagi

Kenjiro Kawatsu

Akira Tashiro

A method of enhancing the efficacy of a monoclonal antibody preparation wherein antigens from patients are tested for their reactivity with the antibody. An amino acid sequence of an expressed protein is deuced from a nucleotide sequence determined by isolation and analysis of a target molecule gene in a biopsy from a patient. This is compared with the previously determined amino acid sequence recognized by the monoclonal antibody preparation in order to assess the fitness of patients for administration of the monoclonal antibody preparation.

Method for enhancing efficacy of preparation of monoclonal antibody

A method for purifying a modified major mite allergen obtained by the genetic recombination technique and a purified modified major mite allergen obtained by said method for purification are provided. A method for purifying a modified major mite allergen obtained by the genetic recombination technique, which comprises the purification steps: (1) Washing and recovering inclusion bodies containing a modified major mite allergen obtained by the genetic recombination technique with MF membrane; (2) Dissolving said inclusion bodies followed by refolding; (3) Concentrating a solution containing the modified major mite allergen with simultaneous removal of low molecular weight components with ultrafiltration membrane; (4) Recovering the modified major mite allergen in non-adsorbed fractions with an anion exchanger; (5) Recovering the modified major mite allergen in adsorbed fractions with a hydrophobic gel; and (6) Recovering the modified major mite allergen in adsorbed fractions with an anion exchanger, and a modified major mite allergen with high purity obtained by said method for purification.

Method for purifying modified major mite allergen

Disclosed is a monoclonal antibody to HBsAg which is prepared by forming hybridomas between human peripheral blood lymphocyte cells, derived from humans having high titers of anti-HBsAg, and myeloma cells, cloning the hybridomas and selecting the antibody-producing clones. The monoclonal antibody can react with all the subtypes of HBsAg and is expected to be very effective in diagnosis and treatment of diseases due to the viral infection.

Method for preparing monoclonal antibody to Hbsag

Growing community of inventors

Kikuchi, Japan

Toshihiro Maeda